Breaking through: Upbeat reports on medical research highlight value of federal, private funding

August 2011
Modern Healthcare;8/29/2011, Vol. 41 Issue 35, p25
Trade Publication
The article discusses various reports on medical research that showcase the impact of federal and private funding. Researchers based at the Feinberg School of Medicine in Northwestern University in Chicago, Illinois reported of the discovery of the failed protein recycling system in the neurons of the spinal cord and the brain, in all forms of amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease. The author states that federal funding is crucial for promotion of long-term public health.


Related Articles

  • health smarts. Millions for ALS.  // PN;Oct2013, Vol. 67 Issue 10, p43 

    The article reports on the 4.3 million dollars in research grants supporting 35 new projects received by the Amyotrophic Lateral Sclerosis (ALS) Association in 2013.

  • ALS awareness. New Research Grants.  // PN;Nov2011, Vol. 65 Issue 11, p21 

    The article focuses on the 20 new research grants in laboratories from the Amyotrophic Lateral Sclerosis (ALS) Association which focuses on the contribution of the new genes TDP43 and FUS to ALS, immune mechanisms in ALS, and development of Riluzole (Rilutek) derivatives with enhanced activity.

  • Research Leader.  // PN;Jul2011, Vol. 65 Issue 7, p29 

    The article profiles the Amyotrophic Lateral Sclerosis (ALS) Association, an organization which seeks to find treatments and cure for Lou Gehrig's disease through its global research efforts.

  • Recent drug approvals.  // FDA Consumer;Mar1996, Vol. 30 Issue 2, p4 

    Describes the drugs approved by the Food & Drug Administration (FDA) in 1995. Invirase (saquinavir) and Epivir (lamivudine or 3TC) for treating HIV infection, including AIDS; Vesanoid (all trans retinoic acid or ATRA) for reversing the progression of promyelocytic leukemia; Rilutek (riluzole)...

  • Insulin-like growth factor significantly improves symptoms...  // Formulary;Jan1996, Vol. 31 Issue 1, p15 

    Reports that the recombinant human insulin-like growth factor appears to slow progression of amyotrophic lateral sclerosis (ALS) and improve functional ability according to the results of a survey. Side effects of drug; Dosage; Comment from Howard Natter, clinical assistant professor of...

  • Rare diseases need a bigger ice bucket. GOOZNER, MERRILL // Modern Healthcare;8/25/2014, Vol. 44 Issue 34, p32 

    The author discusses the Ice Bucket Challenge, a fundraising effort, launched by ALS association, a non-profit organization, for the further research into causes and cures of the combat amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease. He mentions that many others rare...

  • EXONHIT INITIATES PHASE II CLINICAL TRIAL FOR EHT 0201.  // Worldwide Biotech;Dec2002, Vol. 14 Issue 12, p1 

    Reports on the launch by the company ExonHit Therapeutics of a clinical trial evaluating the effectiveness of EHT 0201 (pentoxyfylline) in patients suffering from amyotrophic lateral sclerosis.

  • Doe v. Wilson. Salyer, David R. // Issues in Law & Medicine;Winter90, Vol. 6 Issue 3, p319 

    Presents a United States court ruling related to euthanasia in patients suffering from amyotrophic lateral sclerosis. Case of patient Jane Doe who requested that her physician Dr. James P. Wilson disconnect her respirator; Consideration by Chancellor Allen High on previous legal precedents.

  • Support services important component of Rilutek launch. Rodgers, Katie // Drug Topics;2/5/96, Vol. 140 Issue 3, p46 

    Reports on the planned launch of Rhone-Poulenc Rhorer's (RPR) Rilutek riluzole drug for amyotrophic lateral sclerosis (ALS). Patient support services; Background information; Implications; Plans and expectations.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics